Vitiligo

Combined with routine treatments for vitiligo, certain CPMs proved efficacious in patients with vitiligo, with few adverse effects.

Investigators believe different circulating inflammatory phenotypes in patients with vitiligo may influence their responses to treatment with ruxolitinib cream.

Experts in dermatological conditions provide insight on challenges patients and clinicians may face in accessing vitiligo medications, especially for newer therapies, and the future of vitiligo treatment.

Susan C. Taylor, MD, and George Han, MD, PhD, discuss how to measure treatment response in patients with vitiligo and share advice for counseling patients about long-term use and compliance of treatment.

Dr Susan C. Taylor leads a discussion on newly approved agent, ruxolitinib, and its use in clinical practice as a targeted treatment option for patients with vitiligo.

Experts in dermatology comment on treatment approaches to vitiligo, including home phototherapy devices and recent autologous cell-harvesting technology for burn victims.

Drs Susan C. Taylor and George Han highlight the importance of setting goals, managing patient expectations, and shared-decision making for vitiligo treatment.

Susan C. Taylor, MD, leads a discussion on approaching patient conversations on vitiligo including understanding patient lifestyle, cultural impact, and the impact on QoL.

Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.

AbbVie announced the 24- and 52-week data at EADV 2023.

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.

Experts in dermatological conditions review the different types of vitiligo and comment on distinguishing features that may be affected as well as differentiating from other hypopigmentation skin conditions.

Susan C. Taylor, MD, and George Han, MD, PhD, provide insight on disease awareness for vitiligo, patient demographics, and factors that contribute to vitiligo etiology.

In a population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about the risks of mortality among these patients.

A real-world retrospective analysis also found that among patients receiving treatment, most were unlikely to use more than 1 treatment or switch to an alternative treatment during the first year of diagnosis.

Investigators evaluated the most important markers associated with the pathogenesis of vitiligo, including serum inflammatory and oxidative stress markers.

Vitiligo and psychiatric disorders share a strong connection, with up to 90% of vitiligo patients having comorbid psychiatric conditions.

Clinicians can use culturally competent care to ease patients’ concerns with identity and better understand the emotional toll of the condition.

Chesahna Kindred, MD, MBA, FAAD, and Renata Block, PA-C, review areas of the body that are typically affected, and are more problematic to manage, in patients with vitiligo. Comorbidities that put certain patients at higher risk than others are also discussed.

A panel of experts discuss the diagnosis and pathophysiology of vitiligo.

The VIOLIN study examined the burden of disease, prevalence, and treatment of vitiligo in patients in France.

PRP is both safe and effective and may be used as a therapeutic option or alternative in conditions like vitiligo or in wound healing.

Both modalities achieved positive results and accurate ablation in cultured epithelial sheets transplantation for patients with vitiligo.

Scientists say the new findings could lead to new drugs for vitiligo and other pigmentation diseases.

The multi-million-dollar study will identify signatures of at-risk patients that may predispose them to developing vitiligo.